Mesenchymal Stem Cell Therapy in Stroke: A Systematic Review of Literature in Pre-Clinical and Clinical Research.
Mesenchymal Stem Cell Therapy in Stroke: A Systematic Review of Literature in Pre-Clinical and Clinical Research.
复制标题
DOI：
10.1177/0963689718806846
复制
发表时间：
2018-12
影响因子：
3.3
通讯作者：
Feng W
中科院分区：
文献类型：
--
作者：
Zheng H;Zhang B;Chhatbar PY;Dong Y;Alawieh A;Lowe F;Hu X;Feng W
外源性干细胞治疗（SCT）最近已被认为是一种有前途的神经再生策略，以促进中风幸存者的恢复。间充质干细胞（MSC）是大多数中风临床前和临床研究中使用的干细胞的主要来源。在缺乏关于在卒中患者中使用SCT的循证指南的情况下，了解已发表研究中MSC研究的进展将有助于研究人员和临床医生更好地实现研究成果的转化。我们使用公共数据库PubMed和奥维德Medline以及临床试验注册中心（www.clinicaltrials.gov），对2008年至2017年期间在临床前研究和临床试验中使用MSC的已发表文献进行了系统综述。共确定了78项临床前研究和8项临床研究。虽然大多数临床前和临床研究证明了统计学显著性效应，但这些结果的临床意义仍不清楚。无法测量效应量主要是由于临床前研究中的报告问题，因此限制了我们定量比较研究结果的能力。临床前研究和临床研究的总体质量均不理想。通过对MSC治疗中风的临床前和临床研究进行系统综述，我们评估了当前证据的质量，并确定了将动物研究转化为人体试验的几个问题和差距。解决这些问题并将变化纳入未来的动物研究和人体试验中，可能会在不久的将来使基于干细胞的治疗取得更大的成功。
Exogenous stem cell therapy (SCT) has been recognized recently as a promising neuroregenerative strategy to augment recovery in stroke survivors. Mesenchymal stem cells (MSCs) are the primary source of stem cells used in the majority of both pre-clinical and clinical studies in stroke. In the absence of evidence-based guidelines on the use of SCT in stroke patients, understanding the progress of MSC research across published studies will assist researchers and clinicians in better achieving success in translating research. We conducted a systematic review on published literature using MSCs in both pre-clinical studies and clinical trials between 2008 and 2017 using the public databases PubMed and Ovid Medline, and the clinical trial registry (www.clinicaltrials.gov). A total of 78 pre-clinical studies and eight clinical studies were identified. While majority of the pre-clinical and clinical studies demonstrated statistically significant effects, the clinical significance of these findings was still unclear. Effect sizes could not be measured mainly due to reporting issues in pre-clinical studies, thus limiting our ability to compare results across studies quantitatively. The overall quality of both pre-clinical and clinical studies was sub-optimal. By conducting a systematic review of both pre-clinical and clinical studies on MSCs therapy in stroke, we assessed the quality of current evidence and identified several issues and gaps in translating animal studies to human trials. Addressing these issues and incorporating changes into future animal studies and human trials may lead to better success of stem cells-based therapeutics in the near future.
登录
查看更多内容
影响因子：
6
作者：
Doeppner, Thorsten R.;Herz, Josephine;Hermann, Dirk M.
通讯作者：
Hermann, Dirk M.
影响因子：
6.3
作者：
Janowski, Miroslaw;Lyczek, Agatha;Walczak, Piotr
通讯作者：
Walczak, Piotr
影响因子：
11.2
作者：
Bang, OY;Lee, JS;Lee, G
通讯作者：
Lee, G
影响因子：
8.3
作者：
Fisher M;Feuerstein G;Howells DW;Hurn PD;Kent TA;Savitz SI;Lo EH;STAIR Group
通讯作者：
STAIR Group
影响因子：
2.8
作者：
Suarez-Monteagudo, Carlos;Hernandez-Ramirez, Porfirio;Bergado, Jorge A.
通讯作者：
Bergado, Jorge A.